Ozempic vs Mounjaro: Comparison & Benefits
Ozempic (semaglutide) is a GLP-1 receptor agonist approved for type 2 diabetes and weight loss, while Mounjaro (tirzepatide) is a newer GIP/GLP-1 receptor agonist showing superior weight loss results. Mounjaro targets two pathways compared to Ozempic's single pathway, making it potentially more effective for weight management.
Ozempic
GLP-1 receptor agonist approved by FDA for type 2 diabetes blood sugar control
Patients seeking proven, cost-effective diabetes control with established cardiovascular benefits, or those preferring a more established medication with greater insurance coverage.
Mounjaro
Dual GIP/GLP-1 receptor agonist delivering superior weight loss and diabetes control through dual-pathway mechanism.
Patients prioritizing maximum weight loss, optimal diabetes control, or those who haven't achieved goals with single-pathway GLP-1 agents, and those with adequate insurance coverage.
Quick Answer
AI SummaryOzempic (semaglutide) is a GLP-1 receptor agonist approved for type 2 diabetes and weight loss, while Mounjaro (tirzepatide) is a newer GIP/GLP-1 receptor agonist showing superior weight loss results. Mounjaro targets two pathways compared to Ozempic's single pathway, making it potentially more effective for weight management.
Our Verdict
AI-assistedMounjaro demonstrates superior weight loss and diabetes control due to its dual-mechanism approach, making it the better choice for maximum results. However, Ozempic remains established with more clinical history, better availability, and lower cost, making it ideal for those seeking proven efficacy or budget-conscious patients. The choice depends on individual goals, insurance coverage, and medical history.
Was this verdict helpful?
TIE — neck and neck
Choose Ozempic if
Patients seeking proven, cost-effective diabetes control with established cardiovascular benefits, or those preferring a more established medication with greater insurance coverage.
Choose Mounjaro if
Patients prioritizing maximum weight loss, optimal diabetes control, or those who haven't achieved goals with single-pathway GLP-1 agents, and those with adequate insurance coverage.
Track this comparison
Get notified when prices change, new specs ship, or our verdict updates.
Triggers: price change new spec verdict update
No spam. Stop anytime.
Key Differences at a Glance
- Drug Class:✓ Mounjaro wins(GIP/GLP-1 receptor agonist (dual agonist) vs GLP-1 receptor agonist)
- Average Weight Loss:✓ Mounjaro wins(20-22% body weight vs 15-18% body weight)
- FDA Approval for Weight Loss:✓ Ozempic wins(Approved (Wegovy brand, 2021) vs Approved (Zepbound brand, 2023))
Key Facts & Figures
30 numeric metrics compared
| Metric | Ozempic | Mounjaro | Ratio |
|---|---|---|---|
| Monthly Cost (without insurance)(USD) | ~$900 | — | — |
| Maximum Weekly Dose(mg) | 2.0 mg | — | — |
| FDA Approval Year | 2017 | — | — |
| Number of Dose Strengths Available(strengths) | 4 | — | — |
| Typical Weight Loss at Maximum Dose(% of body weight) | 5-7% | — | — |
| FDA Approval Year(year) | 2017 (diabetes) | — | — |
| Nausea/Vomiting Incidence(% of patients) | 25-40% | — | — |
| Injection Frequency(times per week) | 1 | — | — |
| Average Monthly Cost (Uninsured)(USD) | $900-1,200 | — | — |
| Time to Maintenance Dose(weeks) | 12 | — | — |
| HbA1c Reduction in Diabetics(percentage points) | 1.5-2.0 | — | — |
| Average Weight Loss (Clinical Trial)(% body weight) | 15-18% | 20-22% | |
| A1C Reduction(percentage points) | 1.5-2.0% | 1.8-2.3% | |
| FDA Approval Year (Weight Loss Indication)(year) | 2021 | 2023 | |
| Injection Schedule(per week) | Once weekly | Once weekly | |
| Average Retail Price(USD/month) | $900-1,300 | $1,000-1,500 | |
| Number of Dose Strengths Available(options) | 3 | 7 | |
| Time on Market(years) | 9 years | 3 years | |
| FDA-Approved Maximum Dose(mg/week) | 1mg weekly | — | — |
| Average Weight Loss at 52 Weeks (Clinical Trial)(% body weight) | 2-3% reduction (at diabetes doses) | — | — |
| Average Monthly Cost (US, 2026)(USD) | $900-$1,100 | — | — |
| Nausea Incidence in Clinical Trials(% of patients) | 10-15% (at 1mg dose) | — | — |
| Insurance Coverage Approval Rate(% of major US insurers) | 85-95% (diabetes indication) | — | — |
| Cardiovascular Outcome Reduction (CVOT)(% risk reduction) | 26% MACE reduction (SUSTAIN-6) | — | — |
| Maximum FDA-Approved Weekly Dose(mg) | 2 mg | — | — |
| Average Weight Loss (Clinical Trial)(% body weight) | 5-7% (diabetes indication) | — | — |
| Time to Noticeable Weight Loss(weeks) | 8-12 weeks | — | — |
| Average Uninsured Monthly Cost (2024)(USD) | $900-1,200 | — | — |
| Insurance Coverage Rate (Non-Diabetic Use)(% of plans) | 50-65% (off-label) | — | — |
| Active Ingredient Bioequivalence(% identical) | 100% semaglutide | — | — |
Sourced from publicly available data ·
Key Differences
8 attributes compared head-to-head
- GLP-1 receptor agonistDrug ClassGIP/GLP-1 receptor agonist (dual agonist)(winner)
- 15-18% body weightAverage Weight Loss20-22% body weight(winner)
- Approved (Wegovy brand, 2021)(winner)FDA Approval for Weight LossApproved (Zepbound brand, 2023)
- Once weeklyInjection FrequencyOnce weekly
- 0.5, 1.0, 2.4 mgAvailable Dose Strengths2.5, 5, 7.5, 10, 12.5, 15 mg(winner)
- Widely available since 2017(winner)Market AvailabilityMore recent, expanding supply
- $900-1,300 USD(winner)Cost (Monthly)$1,000-1,500 USD
- 1.5-2.0% reductionType 2 Diabetes Efficacy (A1C Reduction)1.8-2.3% reduction(winner)
- Drug Class
Ozempic
GLP-1 receptor agonist
Mounjaro
GIP/GLP-1 receptor agonist (dual agonist)(winner)
- Average Weight Loss
Ozempic
15-18% body weight
Mounjaro
20-22% body weight(winner)
- FDA Approval for Weight Loss
Ozempic
Approved (Wegovy brand, 2021)(winner)
Mounjaro
Approved (Zepbound brand, 2023)
- Injection Frequency
Ozempic
Once weekly
Mounjaro
Once weekly
- Available Dose Strengths
Ozempic
0.5, 1.0, 2.4 mg
Mounjaro
2.5, 5, 7.5, 10, 12.5, 15 mg(winner)
- Market Availability
Ozempic
Widely available since 2017(winner)
Mounjaro
More recent, expanding supply
- Cost (Monthly)
Ozempic
$900-1,300 USD(winner)
Mounjaro
$1,000-1,500 USD
- Type 2 Diabetes Efficacy (A1C Reduction)
Ozempic
1.5-2.0% reduction
Mounjaro
1.8-2.3% reduction(winner)
Full Comparison
| Attribute | Ozempic | Mounjaro |
|---|---|---|
| Average Weight Loss(%) | 8-12% | — |
| Typical Weight Loss at Maximum Dose(% of body weight) | 5-7% | — |
| Average Weight Loss (Clinical Trial)(% body weight) | 15-18% | 20-22%(winner) |
| A1C Reduction(percentage points) | 1.5-2.0% | 1.8-2.3%(winner) |
| Average Weight Loss at 52 Weeks (Clinical Trial)(% body weight) | 2-3% reduction (at diabetes doses) | — |
Show 1 more attributeAverage Weight Loss (Clinical Trial)(% body weight) 5-7% (diabetes indication) — | ||
| Monthly Cost (without insurance)(USD) | ~$900 | — |
| Average Monthly Cost (Uninsured)(USD) | $900-1,200 | — |
| Average Retail Price(USD/month) | $900-1,300(winner) | $1,000-1,500 |
| Average Monthly Cost (US, 2026)(USD) | $900-$1,100 | — |
| Average Uninsured Monthly Cost (2024)(USD) | $900-1,200 | — |
| Active Ingredient | Semaglutide | — |
| Active Pharmaceutical Ingredient | Semaglutide (recombinant human GLP-1 analog) | — |
| Maximum Weekly Dose(mg) | 2.0 mg | — |
| FDA-Approved Maximum Dose(mg/week) | 1mg weekly | — |
| Maximum FDA-Approved Weekly Dose(mg) | 2 mg | — |
| FDA Approval Year | 2017 | — |
| FDA Approval Year(year) | 2017 (diabetes) | — |
| FDA Approval Year (Weight Loss Indication)(year) | 2021(winner) | 2023 |
| Primary Indication | Type 2 Diabetes | — |
| Cardiovascular Benefits | Proven in diabetic patients | — |
| Typical Insurance Coverage | Widely covered for diabetes | — |
| Number of Dose Strengths Available(strengths) | 4 | — |
| Active Ingredient | Semaglutide (GLP-1 receptor agonist) | — |
| Nausea/Vomiting Incidence(% of patients) | 25-40% | — |
| Nausea Incidence in Clinical Trials(% of patients) | 10-15% (at 1mg dose) | — |
| Injection Frequency(times per week) | 1 | — |
| Injection Schedule(per week) | Once weekly | Once weekly |
| Time to Maintenance Dose(weeks) | 12 | — |
| HbA1c Reduction in Diabetics(percentage points) | 1.5-2.0 | — |
| Active Ingredient Mechanism | GLP-1 receptor agonist (single pathway) | GIP and GLP-1 receptor agonist (dual pathway) |
| Number of Dose Strengths Available(options) | 3 | 7(winner) |
| Time on Market(years) | 9 years(winner) | 3 years |
| Insurance Coverage Approval Rate(% of major US insurers) | 85-95% (diabetes indication) | — |
| Cardiovascular Outcome Reduction (CVOT)(% risk reduction) | 26% MACE reduction (SUSTAIN-6) | — |
| Time to Noticeable Weight Loss(weeks) | 8-12 weeks | — |
| Insurance Coverage Rate (Non-Diabetic Use)(% of plans) | 50-65% (off-label) | — |
| Injection Frequency | Once weekly subcutaneous injection | — |
| Active Ingredient Bioequivalence(% identical) | 100% semaglutide | — |
OzempicMounjaroShow 1 more attribute
Pros & Cons
10 pros·6 cons across both
Ozempic
Pros
- Extensive clinical data and real-world experience since 2017
- Proven cardiovascular benefits and heart attack/stroke risk reduction
- Wider insurance coverage and established supply chains
- Lower average monthly cost
- Once-weekly injection convenient dosing
Cons
- Lower average weight loss compared to Mounjaro (15-18% vs 20-22%)
- Less effective A1C reduction for diabetes management
- Fewer dose options limits personalization
Mounjaro
Pros
- Superior weight loss results (20-22% body weight average)
- Better A1C reduction for type 2 diabetes (1.8-2.3%)
- Dual mechanism targets two appetite and metabolism pathways
- More dose options (7 strengths) for individualized treatment
- Emerging evidence of cardiovascular benefits
Cons
- Higher monthly cost ($1,000-1,500 vs $900-1,300)
- Newer medication with less long-term safety data
- Initial supply constraints and lower availability in some regions
Frequently Asked Questions
5 questions
Both have similar side effect profiles including nausea, vomiting, and diarrhea, especially at higher doses. Mounjaro users report slightly more GI side effects initially due to its dual mechanism, but these typically resolve within 2-4 weeks. Ozempic has more long-term safety data due to its earlier release. Serious side effects like pancreatitis are rare with both medications.
Resources & Learn More
Curated sources to dive deeper
Where to Buy
As an affiliate, we may earn a commission from qualifying purchases at no extra cost to you. Learn more about our affiliate disclosure
Wikipedia
Related Comparisons
12 more to explore
Ozempic vs Wegovy
healthOzempic vs Wegovy
healthYoga vs Pilates
healthIbuprofen vs Acetaminophen
healthInvisalign vs Traditional Braces
healthWhey Protein vs Casein Protein
healthCrossFit vs Gym Training
healthFlu Shot vs COVID Vaccine
healthOrganic Food vs Non-Organic Food
healthTherapy vs Medication
healthMeditation vs Yoga
healthContact Lenses vs Glasses
health
Related Articles
1 article
Explore More
Related comparisons and categories